HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Kiora Pharmaceuticals (NASDAQ:KPRX) and increased its price target from $3.50 to $2.00. Despite a recent 0.84% decrease in share price to $0.66, the new target suggests a potential 202.57% increase. Kiora Pharmaceuticals is a clinical-stage company focusing on eye disease treatments.
February 09, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Kiora Pharmaceuticals, raising its price target to $2.00, indicating a potential 202.57% increase from the current price.
The maintenance of a Buy rating and the increase in price target by a reputable analyst firm like HC Wainwright & Co. can significantly influence investor sentiment and potentially drive up KPRX's stock price in the short term. The substantial potential increase suggested by the new price target may attract more investors to the stock, contributing to its upward movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100